Sugi Predict

Sugi Predict / Compounds / SCHEMBL16113553

SCHEMBL16113553

SCHEMBL16113553

CCNc1ncc(C(=O)O)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 1/20 0.52
▸ MAPK14 Q16539 6/20 0.51
▸ FFAR2 O15552 1/20 0.47
▸ RAB9A P51151 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HCAR3 P49019 1/20 0.44
▸ CDK2 P24941 2/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CDK5 Q00535 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ LCK P06239 2/20 0.41
▸ SCD O00767 1/20 0.40
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13623803 0.85 HCAR2 (0.45) HCAR2MAPK14FFAR2RAB9ANPC1
SCHEMBL4557739 0.84 MAPK14 (0.50) MAPK14FFAR2RAB9ANPC1CYP1A2
SCHEMBL14417494 0.81 NPC1 (0.71) MAPK14RAB9ANPC1CYP1A2CYP3A4
SCHEMBL4252915 0.81 HCAR2 (0.46) HCAR2MAPK14FFAR2RAB9ANPC1
SCHEMBL23334312 0.80 CDC7 (0.54) MAPK14RAB9ACDK2CCNE1SMN1; SMN2
SCHEMBL4256153 0.79 RAB9A (0.65) HCAR2MAPK14FFAR2RAB9ANPC1
SCHEMBL24035968 0.79 MAPK14 (0.42) HCAR2MAPK14FFAR2RAB9ANPC1
SCHEMBL14288431 0.78 MAPK14 (0.54) HCAR2MAPK14FFAR2RAB9ANPC1
SCHEMBL14313604 0.78 MAPK14 (0.54) HCAR2MAPK14FFAR2RAB9ANPC1
SCHEMBL14288406 0.78 MAPK14 (0.54) HCAR2MAPK14FFAR2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-11731972-B2 Spiro compounds as glycosidase inhibitors ASCENEURON SA (CH) 2023-08-22 — — US disclosed
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2023-04-20 — — US disclosed
US-11591327-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2023-02-28 — — US disclosed
US-20220411440-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-12-29 — — US disclosed
US-20220143042-A1 FUSED GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-05-12 — — US disclosed
EP-3186243-B1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-21 — — EP disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 — — US disclosed
US-20210206766-A1 SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-08 — — US disclosed
US-11046712-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2021-06-29 — — US disclosed
US-20170298082-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2017-10-19 — — US disclosed
WO-2017144635-A1 PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES ASCENEURON S. A. (CH) 2017-08-31 — — WO disclosed
WO-2017144637-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON S. A. (CH) 2017-08-31 — — WO disclosed
EP-3186243-A1 GLYCOSIDASE INHIBITORS Asceneuron SA (CH) 2017-07-05 — — EP disclosed
WO-2016030443-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2016-03-03 — — WO disclosed
US-20160031871-A1 Glycosidase Inhibitors YU HENRY (US) 2016-02-04 — — US disclosed
EP-2970272-A1 GLYCOSIDASE INHIBITORS Merck Patent GmbH (DE) 2016-01-20 — — EP disclosed
WO-2014159234-A1 GLYCOSIDASE INHIBITORS MERCK PATENT GMBH (DE) 2014-10-02 — — WO disclosed
CN-1830977-B Novel process for preparation of 2-aminothiazolecarboxamide derivatives LG LIFE SCIENCE CO LTD 2011-10-12 — — CN disclosed
CN-1830977-A Novel process for preparation of 2-aminothiazolecarboxamide derivatives LG LIFE SCIENCE CO LTD (KR) 2006-09-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031871-A1 Glycosidase Inhibitors GAA, BACE1, GBA3 HCAR2 1007/4885MAPK14 4681/4885FFAR2 3506/4885
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 HCAR2 786/4885MAPK14 3279/4885FFAR2 2333/4885
US-20220411440-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 HCAR2 2828/4885MAPK14 4465/4885FFAR2 4286/4885
US-11591327-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 HCAR2 786/4885MAPK14 3279/4885FFAR2 2333/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP HCAR2 2646/4885MAPK14 4415/4885FFAR2 4867/4885
US-20170298082-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 HCAR2 2828/4885MAPK14 4465/4885FFAR2 4286/4885
US-20220143042-A1 FUSED GLYCOSIDASE INHIBITORS BACE1, ENGASE, GBA3 HCAR2 1228/4885MAPK14 4560/4885FFAR2 3938/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP HCAR2 2847/4885MAPK14 4547/4885FFAR2 4868/4885
US-20210206766-A1 SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS GLA, BACE1, GAA HCAR2 1679/4885MAPK14 4140/4885FFAR2 4345/4885
US-11731972-B2 Spiro compounds as glycosidase inhibitors GLA, BACE1, GAA HCAR2 1679/4885MAPK14 4140/4885FFAR2 4345/4885
US-11046712-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 HCAR2 2828/4885MAPK14 4465/4885FFAR2 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback